Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"

NCT00744536 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT00744536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00744536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2012
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiogenesis, leukemia, myelomonocytic, chronic, myelodysplastic syndromes